High JC virus load in tongue carcinomas may be a risk factor for tongue tumorigenesis by Kutsuna, Tomohiko et al.
ORIGINAL ARTICLE
High JC virus load in tongue carcinomas may be a risk
factor for tongue tumorigenesis
Tomohiko Kutsuna & Huachuan Zheng &
Hekmat Osman Abdel-Aziz & Yoshihiro Murai &
Koichi Tsuneyama & Isao Furuta & Yasuo Takano
Received: 21 August 2007 /Revised: 17 October 2007 /Accepted: 21 October 2007 /Published online: 19 February 2008
# The Author(s) 2008
Abstract The John Cunningham virus (JCV) asymptomati-
cally infects a large proportion (~90%) of the population
worldwide but may be activated in immunodeficient
patients, resulting in progressive multifocal leukoencepha-
lopathy. Recent reports demonstrated its oncogenic role in
malignancies. In this paper, the presence of JCV-targeting T
antigen was investigated in tongue carcinoma (TC, n=39),
dysplastic tongue epithelium (DTE, n=15) and glossitis
(n=15) using real-time polymerase chain reaction (PCR)
and in situ PCR and immunohistochemistry, and JCV
copies were analyzed with the clinicopathological parame-
ters of TCs. The results demonstrated that glossitis and
DTEs had significantly lower copies of JCV (410.5±44.3
and 658.3±53.3 copies/μg DNA respectively) than TCs
(981.5±14.0, p<0.05). When they were divided into three
groups with 0–200 copies/μg DNA (low), 201–1,000
(moderate) and more than 1001 (high), TCs showed 3
(7.6%) in the low group, 21 (53.8%) in the moderate group
and 15 (38.4%) in the high group and glossitis showed 11
(73.3%) in the low group, 0 (0%) in the moderate group
and 4 (26.6%) in the high group. The DTEs occupied an
intermediate position between them (p<0.001). In situ PCR
demonstrated that the nuclei of TC and DTE cells are
sporadically T-antigen positive but not in nasal turbinate
epithelial cells. Immunohistochemistry for T-antigen protein
revealed four positive cases only in TCs. The existence of
JCV T-antigen DNA was not associated with the clinico-
pathological variables of TCs. In conclusion, the presence of
JCV may be a risk factor of tongue carcinogenesis.
Keywords Tonguecancer.JCvirus.Carcinogenesis
Introduction
John Cunningham virus (JCV), firstly isolated from the
brain of patients with progressive multifocal leukoenceph-
alopathy [12], is a member of the polyomavirus group
together with simian virus 40 (SV40) and BK virus. These
share major characteristics, such as non-enveloped virions,
double-stranded circular DNA genomes, and oncogenic
potential under the appropriate conditions [7]. It has been
generally thought that JCV has neurotropic oncogenicity
both in rodents and humans [14]. The JCV infects a large
proportion of the population worldwide, and 80–90% of all
adults are seropositive for the virus. Primary infection
occurs during childhood and remains asymptomatic with
the virus persisting quiescent in the kidneys and lymphoid
tissues. However, JCV may be activated when the immune
system is impaired [18]. JCV can be detected in tonsillar
tissue [10], and the respiratory and digestive tracts are
thought to be the primary sites for JCV to enter human
body. A recent report described that lung tissue expresses
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JCV has been detected in human brain tumors [2, 3] and
also in several epithelial malignancies, such as colon,
prostate, and esophageal carcinomas [4, 6, 19]. A trans-
genic mouse strain expressing the JCV Tantigen is reported
to exhibit pituitary tumors in approximately 50% of the
animals by 1 year of age, some progressing to malignant
peripheral nerve-sheath tumors [14]. Tantigen is considered
to play an important role in JCVoncogenesis as it interferes
with two tumor suppressor proteins that regulate cell-cycle
progression, including pRb and p53. Tantigen binds to pRb
and displaces E2F, thereby promoting cell-cycle progres-
sion and the inappropriate cell proliferation of ontogeneti-
cally transformed cells [9]. The release of E2F from Rb
normally activates p14ARF expression that leads to
stabilization of p53. However, T antigen binds to and
inactivates p53 to prevent inhibition of the cell cycle,
providing an optimal cell environment for viral replication
and packaging during the JCV lytic infection and then
facilitating the transformation in non-permissive cells [17].
T antigen can increase the stability of β-catenin and cause
its accumulation by directly binding so that the protein then
translocates to the nucleus where it enhances the expression
of such genes as c-myc and cyclin D1, which are typical of
the deregulation in the Wnt signaling pathway [8]. In this
paper, we examined JCV-targeting T antigen in combina-
tion with real-time polymerase chain reaction (PCR), in situ
PCR, and immunohistochemistry to clarify the oncogenic
role of JCV in tongue carcinogenesis.
Materials and methods
Cases
Formalin-fixed and paraffin-embedded samples were se-
lected from the pathological archive of the University of
Toyama Hospital from 1982 to 1999 with informed consent
of the patients [39 cases of tongue squamous cell carcinoma
(TC), 58.5±15.2 years (mean±SD), male/female=23:16;
15 cases of dysplastic tongue epithelium (DTE), 60.2±
10.4 years, 11:4; 15 cases of glossitis; 67.7±9.8 years, 9:6].
Among the 39 TCs, 14 cases had lymph node metastasis,
and the average longitudinal tumor size was 3.1±0.95 cm
(mean±SD). The staging for each tongue carcinoma was
evaluated according to the Union Internationale Contre le
Cancer system showing stage I in 7 cases, stage II in 15,
stage III in 11, and stage IV in 6. Twenty-seven patients
were followed-up for more than 5 years and are still alive,
but 12 patients died due to tumor progression within
5 years. The Ethics Committee of the Hospital gave
approval for genetic experiments restricted to JCV.
DNA extraction
Paraffin-embedded specimens were cut into consecutive
10 μm sections for microdissection with reference to
hematoxylin-and-eosin staining. Then tissues were depar-
affinized in xylene followed by incubation with proteinase K
and sodium dodecyl sulfate at 55°C overnight. DNA was
extracted using phenol–chloroform–isoamyl method
(25:24:1 ratio) and dissolved in Tris-EDTA buffer (TE,
10mM Tris-HCI+1mM EDTA, pH 7.4) after ethanol
precipitation. Before DNA extraction, their DNAs were
amplified using glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) primers (sense, 5′-ACATCAAGAAGGT
GGTGAGC-3′ and anti-sense, 5′-CTGTTGCTGTAGCC
AAATTCGT-3′; 199 bp) by 35 cycles of denaturation at
95°Cfor60s,annealing53°Cfor60s,andextensionat72°C
for 60 s followed by an additional 7 min at 72°C to confirm
the integrity of the DNA. All reactions were modulatedusing
the Gene Amp 9700 PCR System™ (Applied Biosystem,
Forster City, USA). Ten-microliter aliquots of each PCR
product were examined by electrophoresis on 8% polyacryl-
amide gels. Finally, the gels were stained with ethidium
bromide and photographed under ultraviolet light. The cases
examined in the present study were limited to the ones that
showed a clear single band of GAPDH.
Quantitation of JCV DNA by real-time PCR
A real-time, fluorescence probe-based PCR method was
employed for quantitative assessment of JCV in samples
using the Mx3000P™ Real-Time PCR system (Stratagene,
La Jolla, CA, USA). For establishment of the quantitative
technique, a JCV-containing plasmid (pBS-JCVMad1,
kindly provided by Associate Professor H Sawa, Depart-
ment of Neuropathology, Hokkaido University, Graduate
School of Medicine) was serially diluted and served as a
standard reference. This standard and DNA samples of
TCs, DTEs, and nasal turbinate epithelial cells (NTEs) were
subjected to PCR amplification of the 128-bp sequence of
the T-antigen using RT-JCV1, nucleotides 3492–3511, 5′-
GCCACCCCAGCCATATATTG-3′ and RT-JCV-2, nucleo-
tides 3619–3595, 5′-GTTGACAGTATCCATATGACCAG
AGAA-3′ as the forward and reverse primers, respectively.
The monitoring of the amplicon development was per-
formed using a double-dye probe, RT-JCV-3, nucleotides
3515–3539, 5′-[FAM]-TAAAACAGCATTGCCATG
TGCCCC A-[TAMRA]-3′. The reactions were performed
using the 2x TaqMan® Universal PCR Master Mix
(Applied Biosystems). Reaction mixtures (25 μl) contained
12.5 μl TaqMan® Universal PCR master mix with 2.25 μl
(10 μM) of each primer, 2.5 μl (2.5 μM) of double-dye
probe, and 100 ng of template DNA. The protocol included
the following parameters: an initial 10 min of incubation at
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by 60 cycles of denaturation at 95°C for 30 s, annealing at
55°C for 1 min, and extension at 72°C for 30 s.
In situ PCR
Sections (10 μm thick) were digested with proteinase K
(10 μg/ml) for 15 min at 37°C, then topoisomerase I was
applied for 30 min at room temperature. After rinsing with
phosphate-buffered saline (PBS), the tissue was fixed in 4%
neutralized paraformaldehyde and subjected to washing with
2× saline sodium citrate (SSC). Then a 125-μl aliquot of the
PCR solution (1 μM primers of JCT-1A, nucleotides 3052–
3069, 5′-CCTGTAAAGTTCTAGGCA-3′ and JCT-1AS,
nucleotides 3225–3207, 5′-AGTCAAGGGATT TACCTTC-
3′,2 0 0μM DIG-11-dUTP, 4.5 mM MgCl2,P C Rb u f f e r ,2U
Taq polymerase) was placed on the tissue under membrane
sealing, and then PCR was performed on the slide griddle of
a programmable thermal controller: 94°C for 3 min, fol-
lowed by 15 cycles of 92°C for 15 s, 55°C for 15 s, 72°C for
30 s, and finally 72°C for 5 min. These primers result in the
amplification of a 174-bp fragment of JCV. In the next step,
the tissue was washed with 2× SSC and incubated with
blocking solution, 100 μg/ml Salmon Testis DNA (Sigma,
Germany), 10 μg/ml yeast tRNA (Sigma), and 5% bovine
serum albumin in PBS, for 1 h. Finally, the sections were
incubated with an anti-digoxigenin antibody coupled to
alkaline phosphatase overnight, followed by DAKO®
Fuchsin + Substrate-Chromogen System (DakoCytomation)
andthenwerecounterstainedwithmethylgreen.JCVinfected
neuroblastoma (JCI) cells (kindly provided by Dr. Kazuo
Nagashima, Hokkaido University, Sapporro, Japan) were
used as positive controls in this experiment.
DNA direct sequencing for PCR products
PCR amplicons were further confirmed by direct sequenc-
ing because there is some homology between polyomavi-
ruses SV40, BK virus, and JCV [20]. After 35 cycles of
PCR under the same conditions as real-time or in situ PCR,
DNA was purified on MicroSpin Columns (Amersham
Biosciences) before sequencing according to the manufac-
turer’s instructions using a BigDye® Terminator v3.1 cycle
sequencing kit and an ABI PRISM® 3100 genetic analyzer
(Applied Biosystems). All sequences were analyzed for
homology using the nucleotide–nucleotide “BLAST”
search feature located on the National Center for Biotech-
nology Information Web site.
Immunohistochemistry
For immunohistochemistry, 4 μm thick sections of formalin-
fixed and paraffin-embedded TCs, DTEs, NTEs, and JCI
cellsweredeparaffinizedwithxylene,dehydratedthroughan
alcohol gradient, immersed in heated target-retrieval buff-
ered solution (DAKO) with intermittent microwave irradia-
tion for 15 min. A methanol solution with H2O2 was applied
for 5 min to block endogenous peroxidase. The primary
antibody used was a mouse monoclonal anti-simian virus T
antigen that cross-reacts with JCV T antigen (1:100
dilution; clone Pab 101; Santa Cruz Biotechnology, Santa
Cruz, CA, USA). The tissue was incubated with the
primary antibody overnight, followed by exposure to
DAKO EnVision™ Labeled Polymer (DAKO) for
30 min. Staining was developed by a reaction with
diaminobenzidine chromogen, and counterstaining for
1 min with hematoxylin was then performed.
Statistical analysis
A statistical evaluation was performed using the chi-square
test to compare the positive rate and Mann-Whitney U test
to differentiate the non-parametric means. SPSS 10.0
software was employed to analyze all data, and p<0.05
was considered to be statistically significant.
Results
Real-time PCR for T antigen was successful with all cases
examined with a quantitative standard using plasmid pBS-
JCVMad1. The PCR products for the T-antigen sequence
amplified by real-time PCR were verified to be JCV (not
the BK or SV40 species of polyomavirus) by DNA
sequencing. The viral DNA loads were 981.6±14.0
copies/μg DNA (mean±SE; standard error range 37.8–
2,338.4) in TCs, 658.3±53.3 copies/μg DNA (3.5–2,883)
in DTEs and 410.5±44.3 copies/μg DNA (0–2,070.0) in
glossitis. There were significant differences between TCs
and DTEs and glossitis (p<0.05, Fig. 1a). When the JCV
copy numbers in the TCs, DTEs and glossitis were divided
into three groups, low (0–200 copies/μg DNA), moderate
(201–1000), and high (≥1001), there were significant
differences among them (p<0.01, Table 1). Figure 1b,c,
and d show the average copy numbers in each group. The
value for the control of JCI cells was 4.39×10
6 copies/μg
DNA. In the TCs, the correlation between JCV copy
number (low, 0–1000; high, ≥1001) and such clinicopath-
ological variables as tumor size, stage, differentiation, and
lymph node metastasis was examined, but no correlation
was observed (Table 2).
In situ PCR amplification and immunohistochemical
staining was accompanied by a positive control for JCV
using the genomic DNA from JCI cells, which persistently
is infected with JCV. In situ PCR demonstrated clear
positive staining in 20–30% of the JCI cells (Fig. 2a). Some
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cases, positive cells were sporadically found in areas of the
TCs (Fig. 2c). In the glossitis, no signals were observed in
any of the cases. However, each of these PCR amplicons
was confirmed further through DNA sequencing; and in
each instance, the presence of JCV was validated. In this
study, we observed JCV T-Ag expression occasionally in
TC samples (4 of 39, 10.3%). Figure 3 shows the
immunohistochemical data obtained from JCI cell line and
TC. Positive nuclear staining was observed in the positive
control JCI cells (Fig. 3a). The nuclear expression pattern
of Tantigen also appeared in TC (Fig. 3b), and no detection
of T antigen was noted in glossitis. Direct cycle sequencing
indicated no variation in the DNA sequences of PCR
amplicons (data not shown).
Discussion
In the present study, the results of real-time PCR for
determining JCV T-antigen load revealed significantly
higher levels in TCs compared with DTEs and glossitis.
An earlier report described that colon cancers and adeno-
mas similarly demonstrated a higher JCV T-antigen load
calculated by real-time PCR than background tissue or
normal colonic mucosa [15]. From the available data, the
viral DNA loads in formalin-fixed and paraffin-embedded
samples in colon [15], gastric [11], and lung [20] cancers
appear to be similar to our finding. According to the results
of the real-time PCR, the JCV copy number was calculated
to be around one copy per ten cells in TCs on the basis of
the DNA extraction procedure from oral squamous cell
carcinoma cells (about 100,000 cells/μg DNA, data not
shown). If the presence of JCV is associated with the
development of cancer, then one might expect to find one
virus genome per human genome in cancer tissue but not in
normal tissue. In a previous study of gastric cancers using
fresh frozen samples, the JCV DNA loads were found to be
about 4,800 copies/μg DNA in gastric cancers, about 5,400
Table 1 JCV viral DNA loads divided into low, moderate and high
groups in TCs, DTEs, and glossitis
Groups 0–200 copies/μg
DNA
201–1,000 copies/μg
DNA
≥1001 copies/μg
DNA
TC 3 21 15
DTE 5 7 3
NTE 11 0 4
Footnotes: p<0.01
Table 2 Correlation between the clinicopathological variables and
JCV viral DNA loads
Groups 0 – 1000
copies/μg DNA
1001 –
copies/μg DNA
p value
Size 29.7±7.7 cm 32.8±11.4 cm >0.05
Stage
0–II 14 8
III, IV 10 7
Differentiation >0.05
Well 16 8
Mod, poor 8 7
Metastasis >0.05
− 17 8
+7 7
Fig. 1 JCV viral DNA loads
(data are mean±SE). Distribu-
tion of JCV copies in tongue
carcinoma, dysplastic tongue
epithelium, and glossitis (a). If
JCV viral DNA loads are divid-
ed into low, moderate, and high
groups, numbers of different
groups were indicated for TC
(b), DTE (c), and glossitis (d).
Compared with TCs, glossitis
and DTC had significantly lower
copies of JCV (p<0.05). After
grouping, there were significant
differences among them
(p<0.01)
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gastric tissues. When the corresponding samples were
processed by formalin fixation and paraffin embedding,
the JCV DNA load was reduced to one sixth in gastric
cancers, 1=20 in adjacent non-cancerous tissues, and one
fifth in normal gastric mucosa [11]. The value of 981.5
copies/μg DNA in TCs in the present study may thus
correspond to 4,900 (×5) to 19,630 (×20) in fresh frozen
samples. Those numerical values of JCV copies may
indicate its oncogenic role in the malignancies, including
TCs.
When the viral DNA loads were divided into three
groups, low, moderate and high, the TCs included 15 high
cases (38.4%), 21 moderate (53.8%), and 3 low (7.7%), on
the contrary, glossitis had only 4 high cases (26.6%) and
almost none of JCV DNA in the other 11 cases. DTEs
occupied an intermediate position between them. It is
possible that a JCV infection of the glossitis is a major
risk factor for tongue carcinomas, and some of them
develop into dysplasia and finally carcinoma. In fact,
Epstein–Barr virus was not detected by in situ RNA
hybridization in our cases. It was the same for human
papilloma virus type 16 and 18 by PCR (data not shown).
The presence of high viral DNA loads was not correlated
with any clinicopathological variables that may support the
hypothesis that JCV infection is not directly linked to
cancer progression. However, it is still possible that JCV
may play some role in the oncogenesis of tongue
carcinoma.
While Zambrano et al. [19] used in situ hybridization
(ISH) to reveal the sporadic presence of JCV in normal
prostatic glandular epithelium, data on the actual infection
levels were not available. No signals were detected by ISH
in the current study except in the positive controls (data not
shown), possibly due to the small copy number. In contrast,
in situ PCR can detect even a few viral copies per cell [16],
and sporadic nests of positive cells were detected in TCs
and DTEs but not in glossitis, which is consistent with the
viral DNA loads observed. T-antigen protein expression
was observed by immunohistochemistry in only four cases
of TCs and DTE as opposed to the observations of Shin et
al. [13]. Although we employed the antibody against SV40
Tantigen, our data should be reliable enough to confirm the
JCV localization because we evaluated the immunolabeling
positivity of JCV T antigen taken together with the data of
real-time PCR. In these experiments, it was difficult to
prove the clear positivity of T-antigen protein, but the
antibody used in the present study had limited success. It is
thought that the half-life of T-antigen protein might be very
short, and it is not easy to detect the T-antigen positivity
Fig. 3 Immunohistochemistry for T-antigen protein. a JCI cells as a
positive control, of which 20–30% cells are positive. b TC, well
differentiated squamous cell carcinoma. Moderately intense but
clearly positive localization is visible in the nuclei
Fig. 2 In situ PCR for
T-antigen. a JCI cells infected
by JCV as positive control, of
which 20–30% cells are positive
for T-antigen. b DTE, low grade
dysplasia in line with so-called
leukoplakia. Clear positive sig-
nals can be seen in the nuclei.
c TC, moderately differentiated
squamous cell carcinoma. Mod-
erately intense but clear signals
are noted in the nuclei
Virchows Arch (2008) 452:405–410 409when formalin-fixed and paraffin-embedded tissues are
used.
An earlier study demonstrated the presence of replicating
JCV DNA in B lymphocytes from peripheral blood, tonsil,
and spleen, and it has been hypothesized that lymphocytes
may thus be one site of JCV persistence [10]. The detection
of viral gene products in renal tubules and the excretion of
JC virions in the urine indicate JCV persistence in the
kidney [1]. In the present study, JCV DNA contamination
from JCV persistent B lymphocytes in the oral mucosa,
which contain B lymphocytes, could not be ruled out.
However, the majority of JCV-infected cells observed by in
situ PCR were tonsil stromal cells rather than B lympho-
cytes with using tonsil tissues (data not shown), which is
consistent with the findings of Monaco et al. [10].
In conclusion, the presence of JCV in normal tongue
tissue may be a risk factor for tumorigenesis of tongue
carcinoma, and the possibility that JCV may play some
oncogenetic role can thus not be ruled out. Further
investigations to explore this possibility therefore appear
to be warranted.
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